Hiram Rivas Perez, MD
Pulmonary Disease · Louisville, KYNPI 1811181753
Payments from drug & device makers
What this record shows
Pulmonx Corporation accounts for 80.3% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $1,626 and has fallen 86.3% since, to $222 in 2025. That places this record below the midpoint for pulmonary disease clinicians in KY, where the typical reported total is $4,124.
Across 24 payments — averaging $87.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pulmonx Corporation$2K
- Inari Medical, Inc.$161
- Stryker$161
- Boehringer Ingelheim$61
- GSK$28
Across 22 payments — averaging $1114.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pulmonx Corporation$18K
- Boehringer Ingelheim$6K
What the payments were for
- Travel & lodging$1,01749%
- Food & beverage$1,07151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pulmonx Corporation | 16 | $1,677 |
| Inari Medical, Inc. | 1 | $161 |
| Stryker | 2 | $161 |
| Boehringer Ingelheim | 3 | $61 |
| GSK | 2 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,088 in reported general payments places this provider in the 35th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 178 | $133,207 |
| Dupixent PenDupilumab | 17 | $65,258 |
| Dupixent SyringeDupilumab | 13 | $50,697 |
| Breo ElliptaFluticasone/Vilanterol | 59 | $27,573 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $12,515 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $7,279 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $6,313 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,491 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 170 | $5,380 |
| Tiotropium Bromide | 12 | $4,660 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $2,684 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,598 |
| Qvar RedihalerBeclomethasone Dipropionate | 12 | $1,978 |
| Roflumilast | 24 | $1,700 |
| Ventolin HfaAlbuterol Sulfate | 17 | $952 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $28 | $168,059253 claims |
| Boehringer IngelheimCombivent Respimat | $61 | $12,51517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Louisville
- John McConnellLouisville$864K
- Harold HallerLouisville$340K
- Samantha BaahLouisville$226K
- Karim El-KershLouisville$180K
- Josephine MeiLouisville$101K
- Maroun GhosseinLouisville$34K
- Moutaz Al NabhanLouisville$24K
- Sally SulimanLouisville$21K
- Mark EsterleLouisville$19K
- Kenneth AndersonLouisville$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.